Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities fraud class action has been filed against Embecta Corp. on behalf of those who purchased or acquired shares between November 25, 2025 and May 4, 2026. The complaint alleges that defendants made positive statements while concealing the true state of Embecta's fiscal results, particularly regarding its pen needle business. On May 5, 2026, Embecta reported second quarter fiscal 2026 results that missed guidance and lowered full-year guidance, revealing a revenue decline of over 14% compared to prior guidance of 0% to a 2% decline, partly due to weakness in pen needle sales. The stock price fell from $9.25 per share on May 4, 2026 to $3.90 per share on May 5, 2026, a single-day decline of over 57.8%. Investors who suffered losses have until August 17, 2026 to file a motion to serve as lead plaintiff.
Embecta CorpSecurities fraud class action filed for concealing weak pen needle sales; stock fell 57.8% after missing guidance.